Lilly, Gilead, Amgen Started at Outperform by Bernstein
Bank of America To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday
Johnson & Johnson's MedTech Challenges Loom Amid Chinese Market Pressures And Orthopedics Overhaul, Analysts Say
Shares of Software Companies Are Trading Higher Amid Possible Market Strength. The Market May Be Moving Amid a Rebound With NVIDIA and UnitedHealth Group.
Least Shorted S&P 500 Stocks in September
Why 5 Of 6 UnitedHealth Analysts Are Cutting Forecasts After Q3 Earnings Release
UnitedHealth Shares Are Trading Higher, Rebounding After Falling on Tuesday Following Q3 Earnings.
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday as Big Banks Gather Investors' Confidence
Morgan Stanley Maintains Equal-Weight on Johnson & Johnson, Raises Price Target to $175
Johnson & Johnson Analyst Ratings
UnitedHealth Group Analyst Ratings
Nasdaq Dips 1% Amid Plunge In Chipmaker Stocks: Fear & Greed Index Moves To 'Greed' Zone
U.S. stocks closed: asml holding's earnings slump causing semiconductor sector collapse, the three major indexes collectively fell.
1. China concept stocks popularly fell, with the Nasdaq Golden Dragon Index in China dropping by 5.92%; 2. ASML Holding announced that it had only 2.6 billion euros in orders in the third quarter of this year; 3. United Airlines' third quarter adjusted earnings per share exceeded expectations; 4. Blackstone Group plans to invest 7.5 billion euros in developing datacenters in Spain.
Cancer Drugs Propel J&J Beyond Wall Street Estimates
Benzinga Market Summary: Indexes Fall Amid Weakness In Chip Stocks And Health Insurers, Schwab Surges After Client Assets Increase 27%, China Stocks Fall On Weak Exports And Continued Stimulus Uncertainty
Shares of Software Companies Are Trading Lower. The Sector May Be Falling Amid Sympathy for Overall Market Weakness After ASML and UnitedHealth Group Reported Q3 Results.
Moderna Continues to Be the Most Shorted S&P 500 Healthcare Stock in September
Eli Lilly's Zepbound to Undergo First-of-its-kind Study on Economic Impact
Nasdaq Down 150 Points; Johnson & Johnson Reports Better-Than-Expected Q3 Results
JNJ Releases Positive Data on Nipocalimab for Myasthenia Gravis in Adolescents